Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Biomea Fusion reported financial results for the third quarter of 2026, highlighting the completion of enrollment in its Phase II COVALENT-211 trial for icovamenib in type 2 diabetes. The company also reported positive Phase I results for its oral GLP-1 RA candidate, BMF-650, and projected its cash runway into the second quarter of 2027.
Term
Q3 2026
“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance enrollment in our Phase II COVALENT-212 clinical trial, bringing us closer to important Phase II data readouts for icovamenib in two distinct diabetes populations that we estimate represent over 30% of treated patients with diabetes in the U.S.”
“We also reported first-in-human results for BMF-650, providing initial clinical support for our design hypothesis, in that BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level.”
NextCure reported a net loss of $31.5 million for the nine months ended September 30, 2026, an improvement from the $46.4 million loss in the prior year period. The company's cash position decreased significantly to $8.7 million as it underwent restructuring and asset impairment charges totaling $3.0 million.
E-Smart Corp. reported a net loss of $127,976 for the fiscal year ended August 31, 2026, compared to a loss of $68,034 in 2025, driven by a significant increase in general and administrative expenses. The company's independent auditor issued a going concern warning due to an accumulated deficit of $238,225 and recurring negative cash flows from operations.
Big Sky Industrial reported Q3 2026 financial results and provided a construction update on its flagship Big Sky Carbon Hub project in Montana. The company confirmed that Phase 1 fabrication is underway with first production targeted for spring 2027, supported by a five-year, 100% take-or-pay helium offtake agreement.
“The third quarter was about execution, and we are pleased with where the project stands. Our in-field gathering and injection lines are complete, and our long-lead equipment has been procured, including the natural gas-fired generators that will power the plant. Plant fabrication is underway, on-site civil work begins in the coming weeks, and construction remains on schedule.”
Ryan Smith, President and Chief Executive Officer
“We are targeting first production in spring 2027, a window that leaves sensible room for commissioning and the Montana winter. From day one, our helium is sold under a five-year, 100% take-or-pay contract. In October, the Department of Energy designated helium a critical material, which underscores the value of the domestic supply we are building in Montana.”
StubHub reported Q3 2026 financial results with revenue increasing 7% year-over-year to $502 million and Gross Merchandise Sales (GMS) reaching $2.6 billion. The company also announced a leadership transition, appointing Michael Noonan as CFO to succeed Connie James effective January 4, 2027. Based on strong performance, StubHub raised its full-year 2026 GMS outlook to a range of $10.175 billion to $10.375 billion.
Term
Q3 2026
“Consumers continue to prioritize live events and value the trusted experience that StubHub provides as the global market leader. We are increasing our full-year GMS outlook to reflect our positive third quarter results and anticipated performance for the remainder of the year. Moving forward, we remain committed to advancing StubHub’s strategic priorities that expand access and choice for fans.”
Eric Baker, Founder, Chairman and Chief Executive Officer
LightPath Technologies reported revenue of $20.8 million for the quarter ended September 30, 2026, a 38% increase compared to the prior year. Despite the revenue growth, the company recorded a net loss of $1.7 million, driven by significantly higher operating expenses in selling, general, and administrative costs and new product development.
Sonos reported fiscal year 2026 revenue growth of 7% to $1.55 billion and a 39% increase in Adjusted EBITDA to $184 million. Alongside the results, the company announced that its Board of Directors authorized a new $150 million common stock repurchase program following the completion of its previous buyback program.
“We said Fiscal 2026 would be the year Sonos returned to growth, and we delivered. We grew in every region, delivered meaningfully higher profitability, and brought five new products to market. Underneath it all, the system strategy is working - every product improves those our customers already own, and with Sonos 27, that will keep getting stronger every year.”
Tom Conrad, Chief Executive Officer of Sonos
“Fiscal 2026 demonstrated how much the earning power of Sonos has structurally improved. We grew revenue 7%, reduced Non-GAAP operating expenses 3% and grew Adjusted EBITDA 39% to $184 million, all while absorbing $56 million of higher memory costs. That’s the foundation we’re building on, and we’re actively managing the levers available to us to optimize our financial performance.”
Context Therapeutics reported Q3 2026 financial results and provided a clinical update on its CTIM-76 program, which showed a 22% confirmed ORR and 5.6 months median PFS in platinum-resistant ovarian cancer. The company ended the quarter with $34.4 million in cash, providing a runway into Q4 2027.
Term
Q3 2026
“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy. Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness, providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.”
Palisade Bio reported third quarter 2026 financial results and provided a clinical update on its PALI-2108 programs, including the initiation of the Phase 2b ASCENTRA-UC trial. The company ended the quarter with $113.6 million in cash and expects topline results from the UC trial in Q4 2027.
“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”
JD Finley, Chief Executive Officer of Palisade Bio
“In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”
JD Finley, Chief Executive Officer of Palisade Bio
Seer, Inc. reported third quarter 2026 revenue of $4.0 million, a sequential increase from $3.1 million in Q2 2026, driven by consumable purchases from established customers and new pharmaceutical platform adoptions. The company ended the quarter with $198.1 million in cash and updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.
Term
Q3 2026
“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform.”
Omid Farokhzad, Chair and Chief Executive Officer
“Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use. With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”
Swarmer, Inc. reported Q3 2026 financial results, highlighting its transition from a software provider to an integrated defense solutions supplier. The company is nearing the close of its acquisition of Ratel Robotics and announced a pending IP acquisition from Vataga Drone to bolster its hardware capabilities. Reported revenue for the quarter was $25,554, primarily from support services, as the pending Ratel acquisition's performance is not yet consolidated.
Term
Q3 2026
“The third quarter marked a pivotal period for Swarmer as we made meaningful progress toward our vision of bringing combat-tested technologies from Ukraine to allied nations.”
Alex Fink, Swarmer’s President and U.S. CEO
“Ground vehicles, air defense and integrated autonomous drone kits represent the three pillars of our expanding market position.”
BridgeBio Oncology Therapeutics reported a net loss of $34.2 million for the third quarter of 2026, an improvement from the $44.8 million loss in the prior year period. Total assets decreased to $346.2 million from $448.4 million at year-end 2025, primarily driven by a significant reduction in cash and cash equivalents as the company continues to fund its research and development operations.
Airgain, Inc. reported sales of $15.3 million for the third quarter of 2026, a 9.3% increase compared to the same period in 2025. The company narrowed its net loss to $0.6 million for the quarter, down from a $1.0 million loss in the prior year, driven by higher gross profit and reduced operating expenses.
Marchex reported third quarter 2026 financial results, returning to revenue growth and GAAP profitability with $16.0 million in revenue and $1.3 million in net income. The company highlighted commercial momentum following its Archenia acquisition, including the expansion of AI Voice Agent deployments and automotive OEM distribution. Additionally, Travis Fairchild was appointed as President of the company.
Term
Q3 2026
“Our third quarter results reflect a new phase of growth and meaningful progress in strengthening Marchex's financial performance, with year-over-year revenue growth, positive GAAP net income, and a significant improvement in Adjusted EBITDA.”
Russell Horowitz, Chairman of Marchex
“By bringing together Marchex's conversational intelligence and analytics with Archenia's AI-powered customer qualification and acquisition technologies, we are creating a differentiated platform that connects customer insights with automated actions and measurable business outcomes.”
Astronics Corporation reported record third quarter 2026 financial results, with sales growing 28.5% to $271.7 million and record operating income of $54.0 million. The company achieved a book-to-bill ratio of 1.00 and maintained its full-year 2026 revenue guidance of $1.02 billion to $1.04 billion.
“We delivered a strong third quarter, with record sales and operating income and an adjusted EBITDA margin near its all-time high. These results reflect disciplined operational execution and strong demand across our markets. Bookings were a solid $271.1 million following the prior quarter that had benefited from a couple of large program awards. We expect momentum to continue as we head into the final quarter of the year.”
Peter J. Gundermann, Chairman, President and Chief Executive Officer
This filing contains a Section 13(r) disclosure regarding a minority non-controlling interest in Malaysia Airports Holdings Berhad held by BlackRock affiliates. The disclosure reports that Iran Airtour resumed flight operations to one of the airports operated by Malaysia Airports Holdings Berhad starting in August 2026.
BridgeBio Oncology Therapeutics reported financial results for the third quarter of 2026, highlighting a cash runway expected to fund operations into 2029. The company reported clinical progress for its RAS-pathway inhibitors, including a 75% objective response rate for BBO-8520 in combination with pembrolizumab in certain lung cancer patients. Management expects monotherapy data updates for BBO-11818 and BBO-10203 in the fourth quarter of 2026.
Term
Q3 2026
“The third quarter was an important period for BBOT as we reported updated clinical data for BBO-8520 and delineated our strategic focus. Driven by encouraging clinical data across all three programs we are executing on multiple combinations with the potential for significant patient benefit.”
Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT
“With a strong balance sheet, multiple data catalysts expected through mid-2027, and cash runway into 2029, we believe BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.”
Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT
Copper Property CTL Pass Through Trust reported net income of $12.99 million for the quarter ended September 30, 2026, a significant increase from $1.29 million in the prior year period, primarily due to the absence of a $10.67 million impairment charge recorded in 2025. The Trust's real estate portfolio consists of 117 retail properties, and it is currently in the process of extending its termination date to January 5, 2027.
PetMed Express reported second quarter fiscal year 2027 net sales of $35.8 million, a 19.4% decrease year-over-year driven by lower prescription sales. The company narrowed its net loss to $6.4 million compared to $8.5 million in the prior year, aided by reduced general, administrative, and advertising expenses. CEO Jeff Willard noted the company is focused on stabilizing operations and reducing customer acquisition costs, which fell 32% from the previous year.
Term
Q2 2027
“We have stabilized the operations of the business and our focus now is on transforming our core direct-to-consumer pharmacy business and making PetMeds a leaner, more profitable company at the size we are today.”
Jeff Willard, Chief Executive Officer and President of PetMeds
“We are already making progress: this quarter we cut our cost to acquire a new customer by 32% from a year ago. Next, we are repositioning the brand so pet parents know exactly why to choose PetMeds, making our marketing work harder, making our website easier to buy from, and keeping more of the customers we win.”
Jeff Willard, Chief Executive Officer and President of PetMeds
Skyworks Solutions reported higher operating expenses in fiscal 2026 due to a weakening U.S. dollar against the Mexican Peso and the enactment of the One Big Beautiful Bill Act (OBBBA). The company also completed a significant acquisition of Qorvo on October 5, 2026, which is expected to increase the complexity of its global tax profile and potential tax liabilities.
RideNow Group reported a net loss of $13.9 million for the third quarter of 2026, compared to a $4.1 million loss in the prior year, driven by lower powersports vehicle revenue and a $5.7 million loss on debt extinguishment. The company transitioned to a single-segment operation following the cessation of its vehicle transportation services business in late 2025.
Darling Ingredients reported a significant increase in net income for the nine months ended October 3, 2026, reaching $794.6 million compared to $11.5 million in the prior year period. This growth was primarily driven by a substantial turnaround in equity income from Diamond Green Diesel and increased total net sales of $5.07 billion.
American Integrity Insurance Group Financial Results
American Integrity Insurance Group reported record Q3 2026 revenue growth of 83% year-over-year, driven by a 57% increase in voluntary new business policies. The company achieved net income of $28.4 million and nearly doubled its net premiums earned to $101.2 million compared to the prior year period.
Term
Q3 2026
“We delivered another strong quarter that reflects the continued execution of our strategy and the increasing strength of our voluntary growth platform. Following record voluntary new business production in the second quarter, we sustained that momentum in the third quarter, writing approximately 41,000 voluntary new business policies, an increase of 57% year over year, and an acceleration from the second quarter’s year-over-year growth rate.”
Robert Ritchie, Chief Executive Officer
“Our growth remains grounded in the disciplined underwriting and thoughtful risk selection that have defined American Integrity for more than two decades. As we approach the important milestone of half a million customers, it remains imperative that we remain focused on the same core principles that have made American Integrity successful through various market cycles.”
Suja Life reported third quarter 2026 net sales of $76.4 million, a 3.3% increase year-over-year, driven by volume gains in cold-pressed juice and wellness shots. The company significantly improved its bottom line, with net loss narrowing to $8.3 million from $14.6 million and Adjusted EBITDA growing to $10.5 million. Management updated its full-year outlook, expecting roughly 70% Adjusted EBITDA growth for fiscal 2026.
Term
Q3 2026
“We continued to gain share of natural healthy beverage in the third quarter while most of the category’s largest players lost share. Even with continued pressure in grocery, we’re winning where shoppers are going, our newer lines are leading the way, and we expect adjusted EBITDA to grow roughly 70% this year, with margin expanding to nearly 20%, while investing deliberately behind our brands.”
Maria Stipp, Chief Executive Officer
“Owning our production gives us more control over our costs and supply, which helps us navigate inflationary pressures such as fuel, packaging and other inputs. We’re concentrating our investment on the brands, channels and programs with the potential of delivering the clearest returns, and we believe this positions Suja for more consistent, profitable growth over time.”
Narragansett Financial Corporation reported net income of $9.1 million for the nine months ended September 30, 2026, a significant increase from $3.2 million in the prior year period. The company is currently undergoing a reorganization into a two-tier holding company structure with Narragansett Bancorp, Inc. as the new mid-tier holding company.
Phoenix Energy One, LLC is a non-accelerated filer reporting 100,000,000 common shares outstanding as of November 9, 2026, all owned by Phoenix Equity Holdings, LLC. The company maintains a complex capital structure involving various debt instruments including Adamantium Bonds, Reg D/Reg A Bonds, and Phoenix Flex Notes to fund its exploration and production operations.
Fold Holdings, Inc. reported a significant decrease in total assets from $153.5 million at year-end 2025 to $52.2 million as of September 30, 2026, primarily driven by a reduction in digital assets held in the investment treasury. The company faces a potential Nasdaq delisting for failing to meet the minimum bid price requirement and is managing an accumulated deficit of $212.4 million.
CalciMedica reported a net loss of $4.35 million for the nine months ended September 30, 2026, a significant improvement from the $18.80 million loss in the prior year period, primarily driven by a $10.5 million gain from the change in fair value of financial instruments. Total operating expenses decreased to $14.37 million from $18.74 million, while the company strengthened its cash position through private placements and warrant exercises.
Texas Community Bancshares reported net income of $2.3 million for the nine months ended September 30, 2026, up from $2.0 million in the prior year period. The company saw an increase in net interest income to $10.8 million, though comprehensive income was negatively impacted by $1.1 million in net unrealized losses on available-for-sale securities.
Core & Main announced preliminary estimated financial results for the third quarter of fiscal 2026, reporting net sales between $2.12 billion and $2.13 billion. The company also updated its full-year Adjusted EBITDA outlook to a range of $950 million to $960 million and disclosed $171 million in quarterly share repurchases.